Support HealthHIV

HealthHIV State of Aging with HIV™ Fifth National Survey

HealthHIV’s Fifth Annual State of Aging with HIV™ National Survey examines crucial issues facing long-term survivors and adults aging with HIV.

Joint Statement and Public Comments on the Proposed Changes to Connecticut’s Medicaid Protected Drug Classes

ADAP Advocacy and HealthHIV issued the following joint statement in response to the proposed changes to services for People Living with HIV/AIDS (PLWHA) under Medicaid as set forth in the Connecticut Governor’s Health and Human Services budget recommendations. ADAP Advocacy and HealthHIV believe that the recommendations, now included in HB 5040, Section 2, adopt a materially flawed approach for a communicable disease, like HIV, where uninterrupted access to treatment is central to individual outcomes and broader HIV prevention and care efforts.

HIV Treatment Reduces Accelerated Biological Aging by Nearly Four Years

Growing evidence suggests that people with HIV experience accelerated biological aging, driven by chronic inflammation and immune dysregulation, contributing to elevated risks of cardiovascular and other age‑related diseases. 

At ESCMID Global 2026, researchers presented new data showing that ART can partially reverse this accelerated aging at the molecular level, reducing biological age by nearly four years.

CMS Town Hall Meeting on Biktarvy Price Negotiations: Comments by Joseph Cherabie

CMS Town Hall Meeting on Biktarvy Price Negotiations: Comments by Kevin Herwig

Comments provided by Kevin Herwig, HIV+Hepatitis Policy Institute, during the Centers for Medicare and Medicaid Services Town Hall Meeting on Biktarvy Price Negotiations, April 22, 2026.

Exploring Partnerships Between Campus Health Centers and Community-Based Nonprofits to Enhance Sexual Health Services for Students

This case study examines how partnerships between colleges and community-based organizations can expand access to culturally responsive HIV and STI services for students. Drawing on real-world collaborations, it highlights effective models for delivering testing, prevention, and linkage to care to college/ university students, focusing on populations disproportionately impacted by HIV and STIs.

People on HIV drugs have ‘substantial’ Alzheimer’s protection: study

People taking drugs for HIV and hepatitis B are less likely to develop Alzheimer’s disease, according to a new study. UVA Health investigators now would like clinical trials to examine the potential of the HIV medications as a means to prevent Alzheimer’s disease.

REINFORCE Resource Guide

This Resource Guide was developed as part of the HealthHIV REINFORCE initiative supporting five healthcare organizations to increase their retention and re-engagement in HIV care rates. These sites, situated around the country, ranged from large multi-site hospitals and health centers to small community-based organizations.

Inflamm-aging: Effects of Chronic Inflammation with HIV

Advances in Antiretroviral therapy (ART) allow people with HIV to live longer with fewer medications. Join us as Dr. Peter Hunt details the connection between chronic inflammation and HIV infection and discusses care considerations and emerging research.

Differentiated Service Delivery Models Have Comparable Effectiveness to Standard of Care in HIV

Differentiated service delivery (DSD) models were able to provide comparable effectiveness in treating people with HIV as the standard of care (SoC) when it came to maintaining care and viral suppression, according to a review published in Reviews in Medical Virology.

What is the HIV Care Continuum?

This resource from HIV.gov describes the HIV care continuum, a public health model that outlines the steps or stages that people with HIV go through from diagnosis to achieving and maintaining viral suppression through care and treatment.

After ARVs

Has the dawn of HIV therapeutic vaccines arrived at AIDS 2022?